A History of Impact in Drug Development
50+ Successful
Marketing Applications
Since 1988
How Feasible is Feasibility in Clinical Trials?
CATO Thought Leadership
Regulatory Pathway Strategy Series
CATO Thought Leadership
Slider

Service Solutions

Cato Research, Your Reliable Partner

Cato Research (CATO) is an international regulatory and clinical contract research organization (CRO) that has been delivering successful outcomes for its clients since 1988. Through highly qualified and experienced personnel located in offices across North America, Europe, Israel, and South Africa, supported by strategic alliances with selected regional CROs, CATO offers tried-and-trusted international coverage.

CATO has the advantage of integrated regulatory, clinical, and scientific expertise. Our highly talented and experienced international team offers services from preclinical through IND (or equivalent), clinical development, and marketing approval to Phase 4 postmarketing research. Our track record includes successes across many different health products, including drugs, biologics, vaccines, cell therapies (including stem cells), nutriceuticals, medical foods, devices, and diagnostics. In terms of diseases and indications, CATO has been involved in a wide variety of projects with a dominant focus in oncology, neurology/CNS, and rare and orphan drug indications. This experience includes leadership of, and involvement in some of the most challenging and innovative products.

Therapeutic Expertise

What our Sponsors say about us...

“…Thanks to all of you!

"...Thanks to all of you!  You guys are terrific!  It's a real pleasure to work with you.  Thanks to all the efforts and professional work.  Looking forward for the next phase on this project!
Please find attached the APPROVAL letter for Product.  Please share in our excitement as you have been partners in this adventure!"

Global U.S. Biotechnology Company

2017-11-21T21:08:17-05:00

Global U.S. Biotechnology Company

"...Thanks to all of you!  You guys are terrific!  It's a real pleasure to work with you.  Thanks to all the efforts and professional work.  Looking forward for the next phase on this project! Please find attached the APPROVAL letter for Product.  Please share in our excitement as you have been partners in this adventure!"

“Dear Cato team,

Thank you so much for all your hard work which has resulted in our NDA being submitted one day earlier than our already extremely tight timeline.


All our partners were very surprised when we set such an ambitious timeline in April when we changed from a paper CR to an eCTD, and many have said they did not think we would make it.  But with your team spirit and hard work the impossible has been made possible."

-Specialty Pharmaceutical Company

2017-11-21T21:16:33-05:00

-Specialty Pharmaceutical Company

Thank you so much for all your hard work which has resulted in our NDA being submitted one day earlier than our already extremely tight timeline. All our partners were very surprised when we set such an ambitious timeline in April when we changed from a paper CR to an eCTD, and many have said they did not think we would make it.  But with your team spirit and hard work the impossible has been made possible."

Upcoming Events

No event found!

Cato Research Blog

  • New FDA Guidances for November and December 2019...
    by Cato Research on January 6, 2020 at 9:36 pm

    By Alice Li, MD, MSc, RAC(CAN), Regulatory Scientist, Cato Research Special Interest Guidances/Information Date Posted Guidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, […]

  • What’s New Health Canada? November 2019 Updates
    by Cato Research on December 20, 2019 at 2:41 pm

    By Alejandra Gomez Perez, M.Sc., Regulatory Affairs Associate What’s New in: Therapeutic Products Directorate: Biologics and Genetic Therapies Directorate: Medical Devices: https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/what-new.html Natural and […]

Twitter @CatoResearch

LinkedIn Cato Research

Facebook @catoresearch

Searching for something else?